Usefulness of milnacipran in treating phantom limb pain

Nagoshi, Yasuhide; Watanabe, Akira; Inoue, Saiko; Kuroda, Tomoki; Nakamura, Mitsuo; Matsumoto, Yoshitake; Fukui, Kenji
December 2012
Neuropsychiatric Disease & Treatment;2012 Part 2, Vol. 8, p549
Academic Journal
Background: Amputation of an extremity often results in the sensation of a "phantom limb" where the patient feels that the limb that has been amputated is still present. This is frequently accompanied by "phantom limb pain". We report here the use of milnacipran, a serotonin and norepinephrine reuptake inhibitor, to treat phantom limb pain after amputation of injured or diseased limbs in three patients. Methods and results: The severity of phantom pain before and during treatment was quantified using a visual analog scale. In one case, phantom limb pain responded partially to treatment with high doses of paroxetine, and then replacement with milnacipran further improved the pain relief and long-term full pain relief was achieved. In the two other cases, milnacipran was used as first-line treatment and phantom limb pain responded rapidly. Conclusion: These results suggest that milnacipran administration may be useful in phantom limb pain, possibly as a first-line treatment.


Related Articles

  • Dapoxetine: a guide to its use in premature ejaculation.  // Drugs & Therapy Perspectives;Feb2011, Vol. 27 Issue 2, p1 

    Dapoxetine, a selective serotonin reuptake inhibitor, is indicated for the treatment of premature ejaculation in men aged 18-64 years. In well designed clinical trials in men with premature ejaculation, treatment with dapoxetine significantly increased intravaginal ejaculation latency times...

  • Review: SSRIs and TCAs equally effective at treating chronic depression and dysthemia; SSRIs are associated with fewer adverse events than TCAs. Kocsis, James H // Evidence Based Mental Health;Aug2013, Vol. 16 Issue 3, p82 

    The article presents an abstract of a review of a study by A. von Wolff and colleagues published in a 2013 issue of the "Journal of Affective Disorders" on the effectiveness and tolerability of selective serotonin reuptake inhibitors (SSRIs) compared with tricyclic antidepressants (TCAs) in the...

  • The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature.  // NAPPP Monthly Newsletter;Oct2016, Vol. 11 Issue 10, p8 

    The article presents a study which examined the safety, tolerability, and risks related to the use of newer generation of antidepressant drugs (AD) for the treatment of major depressive disorders. Among the drugs are serotonin noradrenaline reuptake inhibitors, bupropion, and mirtazapine. Also...

  • SEROTONIN & NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs).  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p746 

    The article presents information on the antidepressant serotonin and norepinephrine reuptake inhibitors (SNRI), including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • Cross-sectional study of alteration of phantom limb pain with visceral stimulation in military personnel with amputation. Rafferty, Michael; Britton, Thomas M. Bennett; Drew, Benjamin T.; Phillip, Rhodri D. // Journal of Rehabilitation Research & Development;2015, Vol. 52 Issue 4, p441 

    While phantom limb pain is a well-recognized phenomenon, clinical experience has suggested that the augmentation of phantom limb pain with visceral stimulation is an issue for many military personnel with amputation (visceral stimulation being the sensation of the bowel or bladder either filling...

  • Selective Serotonin Reuptake Inhibitors for Treatment of Selective Mutism. Çöpür, Mazlum; Görker, Işık; Demir, Türkay // Balkan Medical Journal;Mar2012, Vol. 29 Issue 1, p99 

    Some authors suggest that selective mutism should be considered as a variant of social phobia or a disorder in the obsessive-compulsive spectrum. Recent studies indicate that pharmacological treatments may be effective in the treatment of selective mutism. In this article, four cases who were...

  • Savella.  // Formulary;Feb2009, Vol. 44 Issue 2, p32 

    The article describes the drug milnacipran, marketed as Savella, which was approved in January 2009. Milnacipran is designed to inhibit norepinephrine and serotonin uptake for the management of fibromyalgia. The article describes the efficacy and safety of the drug as demonstrated in studies as...

  • ACP treatment guideline for antidepressants.  // Neurology Alert;Jan2009 Pharmacology Watch, p2 

    The article reports on the practice guideline issued by the American College of Physicians for the use of antidepressants to treat depressive disorders. The guideline encompasses the use of newer second-generation antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRI) and...

  • Pharmacological Profile of SSRIs and SNRIs in the Treatment of Eating Disorders. Capasso, Anna; Petrella, Claudio; Milano, Walter // Current Clinical Pharmacology;Jan2009, Vol. 4 Issue 1, p78 

    Bulimia Nervosa (BN) and Binge Eating Disorder (BED) are some of the most common eating disorders (ED) in industrialized societies, characterized by uncontrolled binge eating and self-induced purging or other compensatory behaviours aiming to prevent body weight gain. It has been suggested that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics